Immune checkpoint blockade Journal Article
| Authors: | Naidoo, J.; Page, D. B.; Wolchok, J. D. |
| Article Title: | Immune checkpoint blockade |
| Abstract: | Since the development and approval of Ipilimumab, the first immune checkpoint inhibitor licensed for the treatment of metastatic melanoma, clinicians have gained a better understanding of the mode of action, management of toxicities, and assessment of response to this class of drugs. Several antibodies are now in development, aimed at blocking novel immune checkpoint molecules, such as PD-1 and it's corresponding ligand PD-L1. This article summarizes the mechanism of action, preclinical development, and subsequent clinical studies of immune checkpoint antibodies in melanoma. © 2014 Elsevier Inc. |
| Keywords: | signal transduction; treatment response; unclassified drug; overall survival; drug tolerability; fatigue; neutropenia; review; hepatitis; cisplatin; advanced cancer; diarrhea; drug efficacy; monotherapy; nonhuman; solid tumor; pancreas cancer; protein function; biological marker; cytotoxic t lymphocyte antigen 4 antibody; dacarbazine; glycoprotein gp 100; ipilimumab; peginterferon alpha2b; ticilimumab; unindexed drug; melanoma; gene expression profiling; anemia; lung non small cell cancer; nausea; vomiting; steroid; kidney carcinoma; vinblastine; immunoregulation; monoclonal antibody; alanine aminotransferase blood level; aspartate aminotransferase blood level; drug dose escalation; hyperglycemia; lymphocytopenia; pneumonia; pruritus; rash; immune response; immunotherapy; drug mechanism; single drug dose; colitis; liver disease; methylprednisolone; loperamide; diet therapy; dermatitis; liver function test; peptide vaccine; corticosteroid; cytotoxic t lymphocyte antigen 4; uvea melanoma; cytokine release; autoimmune disease; endocrine disease; immunopathology; lymphocyte count; cutaneous melanoma; recombinant interleukin 2; enterocolitis; uveitis; programmed death 1 ligand 1; programmed death 1 receptor; metastatic melanoma; budesonide; abnormal laboratory result; hypophysitis; vitiligo; tremelimumab; thyroiditis; mucosal melanoma; infliximab; recombinant alpha interferon; nivolumab; mpdl 3280a; immune checkpoint; medi 4736; trx 518; human; priority journal; anti-pd-1; anti-ctla4; anti-pd-l1; checkpoint inhibitor; dta 1; pembrolizumab; programmed death 1 ligand 2; oral rehydration therapy |
| Journal Title: | Hematology/Oncology Clinics of North America |
| Volume: | 28 |
| Issue: | 3 |
| ISSN: | 0889-8588 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2014-06-01 |
| Start Page: | 585 |
| End Page: | 600 |
| Language: | English |
| DOI: | 10.1016/j.hoc.2014.02.002 |
| PROVIDER: | scopus |
| PUBMED: | 24880949 |
| DOI/URL: | |
| Notes: | Hematol. Oncol. Clin. North Am. -- Export Date: 8 July 2014 -- CODEN: HCNAE -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work